Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. - Wikidata - wikimedia - TriplyDB

Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.

Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q34150474

about

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association Heart disease and stroke statistics--2014 update: a report from the American Heart Association Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association Addressing Disparities in Stroke Prevention for Atrial Fibrillation: Educational Opportunities.Quality of care in patients with atrial fibrillation in primary care: a cross-sectional study comparing clinical and claims data.Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995-2014.Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.Cardiac imaging for assessment of left atrial appendage stasis and thrombosis.Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom.Characterization of patients with atrial fibrillation not treated with oral anticoagulants Impact of atrial fibrillation on healthcare utilization in the community: the Atherosclerosis Risk in Communities study.Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study Paroxysmal atrial fibrillation and the hazards of under-treatment Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK.Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence No Decline in the Risk of Stroke Following Incident Atrial Fibrillation Since 2000 in the Community: A Concerning Trend.Identifying the risks of anticoagulation in patients with substance abuse Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.Underuse of anticoagulation in patients with atrial fibrillation.Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail?Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.Magnetic resonance imaging of the left atrial appendage post pulmonary vein isolation: Implications for percutaneous left atrial appendage occlusion.Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemiologic registry.Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban.Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage.Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.Patient preferences regarding atrial fibrillation stroke prophylaxis in patients at potential risk of atrial fibrillation.Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation.

P2860

Q22306356-03AF178E-784F-4A76-AA67-C8DF324F0F9A Q29547691-F5A3FEAE-592E-470D-BF13-89365D37D17B Q30238784-860057CC-6450-43D8-874C-BE48C890B6CB Q30300349-4316EFC5-3A73-42F3-892F-EFF6E9A9AA02 Q31149219-4FB4AF5A-0542-4BC7-A13A-1CBCFB230EDF Q33565534-1944BA15-9859-4606-AAC1-3F78ED5F2F29 Q33792352-D5E4320B-410A-45CE-862B-443D554A86E6 Q34087971-22BDB840-7ED1-45A4-9DFC-A4B570D95F59 Q34423822-D69E2FD7-D695-44DC-8B62-42AA49B657DA Q34712397-C961FCD3-C64B-49FE-9B58-89861FFBEE21 Q34781621-03150DA3-318B-4413-83F2-B21608896289 Q35114854-203F263A-2165-4FA7-AC05-FF6C97AA166B Q35153009-31E4D66B-A0D8-4CC3-BB7C-5B9B037AB29C Q35784686-927F4244-3A7E-4606-9509-79E00D944D18 Q36012558-93AF583C-431A-434B-A7D2-8ABA4E124801 Q36409803-744B78BA-F1BB-4A21-843B-9C7EC9783FFF Q36551541-C1F31F40-2D35-4D9C-8B6C-B376BC9C4169 Q37076202-E8A31661-B079-4B91-8771-A36BFFD32146 Q37203620-2F875143-A30A-40F4-9198-8E95DD54D9FF Q37307689-73FB234A-15CE-47E2-88E5-DCC8E8ABAE81 Q37590855-835BB9F0-ECE3-437F-A8AB-3EBDBF1E8194 Q38079779-99276233-90C8-44AC-807C-17B8D89B6FAB Q38372780-F34F5A46-56E6-4906-9EED-E7B995202832 Q38529659-A2127CB1-6E99-459C-93B8-6D48B8BA24AC Q38668964-89C2A0C9-3D04-4584-B5DA-9ACD64758E09 Q40386721-97A52018-CEE6-4C0C-8D1B-09D21169803D Q41341553-68221621-A257-4484-B537-B65E44FDD208 Q41503389-3567FBCE-2184-4B80-BC40-B7A9C8357BE1 Q41910531-A7A79ABD-7DED-4698-B2F4-772BF969FC17 Q45394833-CEEAAB3B-4032-4C61-9D32-1400B9A90C47 Q47553794-33C1DB89-6568-4A1F-B129-C11504E0CE59 Q47777774-A7FC49E1-8EB0-4B6E-9AEE-8565AC7B8F60 Q49378467-81CFB1EB-6FC5-4B0D-B4A0-B613152F099F Q49428555-6271AB67-DF11-457E-94D5-4D5F16C796AF Q52589136-F4E86FCB-D96F-4A76-AA95-36341FF2BD9F Q53516526-2552042A-C22A-4407-89FF-DFA554B64202 Q55105150-9001EB9D-8175-487A-9850-3022A66BF7B8

P2860

Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q34150474

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Predictors of warfarin use in ...... atic review and meta-analysis.

@ast

Predictors of warfarin use in ...... atic review and meta-analysis.

@en

Predictors of warfarin use in ...... atic review and meta-analysis.

@nl

type

label

Predictors of warfarin use in ...... atic review and meta-analysis.

@ast

Predictors of warfarin use in ...... atic review and meta-analysis.

@en

Predictors of warfarin use in ...... atic review and meta-analysis.

@nl

prefLabel

Predictors of warfarin use in ...... atic review and meta-analysis.

@ast

Predictors of warfarin use in ...... atic review and meta-analysis.

@en

Predictors of warfarin use in ...... atic review and meta-analysis.

@nl

P1433

Q34150474-7DA3003F-BE69-43B6-BEFB-21288DE60E36

P1476

Q34150474-B044838B-79D1-4E29-88FD-20064CEDF41F

P2093

Q34150474-151263A0-8A1D-4FA0-9FB4-A2F0A0B4EC50

Q34150474-8C1D1E46-2ED8-4587-875A-435B310A511F

Q34150474-9EC38FC8-170B-4F34-8A8D-6C58B06C7DBD

Q34150474-D795F7DD-6A10-4B64-9AC7-CE1B0C632C87

P275

Q34150474-9749E5D8-D921-472B-BD53-B2420FE54D16

P2860

Q34150474-044206BD-B6E3-4CFC-8053-E8F3D5921803

Q34150474-05B2732F-1AA0-4C49-892F-F9F3F010AFFF

Q34150474-05F3BA2A-6EB7-4254-8D3F-DA228BF7C489

Q34150474-06BE92C2-22B8-4A7E-940E-84939A9B4650

Q34150474-098A46A9-CF35-43D8-AADB-710A12B4EFD0

Q34150474-0EFEEDE9-A075-4BC2-84DE-3231B76471E4

Q34150474-1B2DDAE7-DF24-40EC-81AE-580B1B55F1C6

Q34150474-2DBCA2BE-D13B-4D72-BB7E-F0E711E8D734

Q34150474-2E83B7E8-55C6-417B-AFCC-28FCC09138C8

Q34150474-2FE07EC9-8BC0-40B3-B6DE-3DAC8EB82606

P2888

Q34150474-8D0E2D50-0716-426B-863B-D525C64AB5BB

P304

Q34150474-2775ACB8-C9D3-4E9D-BC20-A7C28168AF3E

P31

Q34150474-33A88DAB-7893-4B6B-84D4-BE802A512DD8

Q34150474-56fc60a1-d661-4f45-b92b-e756a9133755

Q34150474-EA7C1628-6E4B-4ECE-B46C-2E74B9F22F88

P356

Q34150474-E54FAF84-5E12-482F-B066-7D97FD302C71

P478

Q34150474-5C636C40-D164-4C59-AB43-4FD5FA1E9F21

P5008

Q34150474-0EC1B303-B365-4604-9A26-CE41F0BF3533

P577

Q34150474-428A634D-20D1-43F0-9EAB-482E8DAC568C

P5875

Q34150474-D812801A-38AC-42F3-A0F7-D273003A31A4

P6179

Q34150474-5B47CF7E-FF8E-4B74-ACBE-8265989E4377

P698

Q34150474-ED5CCD24-F324-44B3-8720-9C4300B83F27

P921

Q34150474-0A9BF776-4673-4DA4-B278-8324A6E63613

Q34150474-2B267A68-E06B-4988-AD2E-35D0908D9E31

Q34150474-4F972E3D-0C8B-44AF-990F-A455768DED19

Q34150474-8523EC5A-0905-4455-9881-50E724F50A1B

Q34150474-E71A3D60-840D-47D9-B358-17612BE7ED8D

P932

Q34150474-46D7B28C-3239-41FC-A0A1-3FD4F6C727DB

P356

P1433

BMC Family Practice

P1476

Predictors of warfarin use in ...... atic review and meta-analysis.

@en

P2093

Craig I Coleman

http://www.w3.org/2001/XMLSchema#string

Jeffrey Kluger

http://www.w3.org/2001/XMLSchema#string

Victoria L Baczek

http://www.w3.org/2001/XMLSchema#string

Wendy T Chen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation

Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention

Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation

Newly detected atrial fibrillation and compliance with antithrombotic guidelines

Dabigatran versus warfarin in patients with atrial fibrillation

Is warfarin really underused in patients with atrial fibrillation?

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2296-13-5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2012-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221805318

http://www.w3.org/2001/XMLSchema#string

P6179

1037431209

http://www.w3.org/2001/XMLSchema#string

P698

22304704

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

cerebrovascular disease

atrial fibrillation

P932

3395868

http://www.w3.org/2001/XMLSchema#string